Alumis (ALMS) EBITDA Margin (2025)
Alumis' (ALMS) quarterly EBITDA Margin came in at 4999.74% in Q4 2025, up 10.41% on a QoQ basis from 5580.45% in Q3 2025.
Alumis (ALMS) EBITDA Margin (2025) Analysis & Trends
Alumis (ALMS) has 1 years of EBITDA Margin data on file, last reported at 4999.74% in Q4 2025.
- On a quarterly basis, EBITDA Margin changed N/A year-over-year to 4999.74% in Q4 2025; TTM through Dec 2025 was 1886.06%, a N/A change from a year earlier, with the FY2025 full-year figure at 1886.92%, changed N/A from the prior year.
- EBITDA Margin for Q4 2025 stood at 4999.74%, up from 5580.45% in the prior quarter.
- Over the last five years, EBITDA Margin for ALMS reached as high as 583.49% in Q1 2025 and fell as low as 5580.45% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alumis | 2.41 Bn | 2.10 Bn | - | -4,999.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,999.74% |
| Sep 30, 2025 | -5,580.45% |
| Jun 30, 2025 | -5,271.53% |
| Mar 31, 2025 | -583.49% |